HUP0203288A3 - Pyrrole derivatives as phosphodiesterase vii inhibitors, pharmaceutical compositions containing them and their use - Google Patents
Pyrrole derivatives as phosphodiesterase vii inhibitors, pharmaceutical compositions containing them and their useInfo
- Publication number
- HUP0203288A3 HUP0203288A3 HU0203288A HUP0203288A HUP0203288A3 HU P0203288 A3 HUP0203288 A3 HU P0203288A3 HU 0203288 A HU0203288 A HU 0203288A HU P0203288 A HUP0203288 A HU P0203288A HU P0203288 A3 HUP0203288 A3 HU P0203288A3
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- pyrrole derivatives
- phosphodiesterase vii
- vii inhibitors
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 title 1
- 150000003233 pyrroles Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19953025A DE19953025A1 (de) | 1999-11-04 | 1999-11-04 | Pyrrolderivate als Phosphodiesterase VII-Hemmer |
PCT/EP2000/010526 WO2001032618A1 (de) | 1999-11-04 | 2000-10-25 | Pyrrolderivate als phosphodiesterase vii-hemmer |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0203288A2 HUP0203288A2 (hu) | 2003-01-28 |
HUP0203288A3 true HUP0203288A3 (en) | 2003-12-29 |
Family
ID=7927861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0203288A HUP0203288A3 (en) | 1999-11-04 | 2000-10-25 | Pyrrole derivatives as phosphodiesterase vii inhibitors, pharmaceutical compositions containing them and their use |
Country Status (22)
Country | Link |
---|---|
US (1) | US6737436B1 (hu) |
EP (1) | EP1230215B1 (hu) |
JP (1) | JP2003513070A (hu) |
KR (1) | KR20020063173A (hu) |
CN (1) | CN1382122A (hu) |
AR (1) | AR026351A1 (hu) |
AT (1) | ATE339403T1 (hu) |
AU (1) | AU782477B2 (hu) |
BR (1) | BR0015334A (hu) |
CA (1) | CA2389709C (hu) |
CZ (1) | CZ20021440A3 (hu) |
DE (2) | DE19953025A1 (hu) |
ES (1) | ES2272331T3 (hu) |
HK (1) | HK1049831A1 (hu) |
HU (1) | HUP0203288A3 (hu) |
MX (1) | MXPA02004440A (hu) |
NO (1) | NO20022125D0 (hu) |
PL (1) | PL355099A1 (hu) |
RU (1) | RU2002113750A (hu) |
SK (1) | SK5952002A3 (hu) |
WO (1) | WO2001032618A1 (hu) |
ZA (1) | ZA200204433B (hu) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6946481B1 (en) * | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
WO2003053975A1 (fr) | 2001-12-13 | 2003-07-03 | Daiichi Suntory Pharma Co., Ltd. | Derives de pyrazolopyrimidinone possedant une activite inhibitrice de pde7 |
DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
DE10226420A1 (de) * | 2002-06-13 | 2004-01-15 | Eucro European Contract Research Gmbh & Co Kg | Verfahren zur Behandlung der Artherosklerose |
JP2006219374A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するイミダゾトリアジノン誘導体 |
JP2006219373A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
CA2569530C (en) * | 2004-07-01 | 2013-07-30 | Daiichi Asubio Pharma Co.,Ltd. | Thienopyrazole derivative having pde 7 inhibitory activity |
CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
MX2009002496A (es) | 2006-09-08 | 2009-07-10 | Braincells Inc | Combinaciones que contienen un derivado de 4-acilaminopiridina. |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
MX2009010450A (es) * | 2007-03-27 | 2009-11-23 | Omeros Corp | El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento. |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
EP2640395A4 (en) | 2010-11-08 | 2014-01-22 | Omeros Corp | TREATMENT OF DISEASES ASSOCIATED WITH SEARCH AND PULSE CONTROL BY PDE7 INHIBITORS |
EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
US11685745B2 (en) | 2017-07-12 | 2023-06-27 | Dart Neuroscience, Llc | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors |
WO2024038090A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE154827C (hu) | ||||
DD154827A1 (de) * | 1980-11-28 | 1982-04-21 | Karl Gewald | Verfahren zur herstellung von azofarbstoffen aus substituierten 3-aminopyrrolen |
DE69725171T2 (de) * | 1996-12-10 | 2004-07-15 | G.D. Searle & Co., Chicago | Substituierte pyrrolylverbindungen zur behandlung von entzündungen |
-
1999
- 1999-11-04 DE DE19953025A patent/DE19953025A1/de not_active Withdrawn
-
2000
- 2000-10-25 DE DE50013473T patent/DE50013473D1/de not_active Expired - Lifetime
- 2000-10-25 CN CN00814828A patent/CN1382122A/zh active Pending
- 2000-10-25 CA CA002389709A patent/CA2389709C/en not_active Expired - Fee Related
- 2000-10-25 US US10/129,261 patent/US6737436B1/en not_active Expired - Fee Related
- 2000-10-25 PL PL00355099A patent/PL355099A1/xx unknown
- 2000-10-25 ES ES00975917T patent/ES2272331T3/es not_active Expired - Lifetime
- 2000-10-25 JP JP2001534770A patent/JP2003513070A/ja active Pending
- 2000-10-25 HU HU0203288A patent/HUP0203288A3/hu unknown
- 2000-10-25 KR KR1020027005646A patent/KR20020063173A/ko not_active Application Discontinuation
- 2000-10-25 BR BR0015334-6A patent/BR0015334A/pt not_active Application Discontinuation
- 2000-10-25 WO PCT/EP2000/010526 patent/WO2001032618A1/de active IP Right Grant
- 2000-10-25 EP EP00975917A patent/EP1230215B1/de not_active Expired - Lifetime
- 2000-10-25 SK SK595-2002A patent/SK5952002A3/sk unknown
- 2000-10-25 AU AU13873/01A patent/AU782477B2/en not_active Ceased
- 2000-10-25 CZ CZ20021440A patent/CZ20021440A3/cs unknown
- 2000-10-25 RU RU2002113750/15A patent/RU2002113750A/ru unknown
- 2000-10-25 MX MXPA02004440A patent/MXPA02004440A/es unknown
- 2000-10-25 AT AT00975917T patent/ATE339403T1/de not_active IP Right Cessation
- 2000-11-03 AR ARP000105800A patent/AR026351A1/es unknown
-
2002
- 2002-05-03 NO NO20022125A patent/NO20022125D0/no not_active Application Discontinuation
- 2002-06-03 ZA ZA200204433A patent/ZA200204433B/en unknown
-
2003
- 2003-03-14 HK HK03101865.7A patent/HK1049831A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
PL355099A1 (en) | 2004-04-05 |
SK5952002A3 (en) | 2002-09-10 |
AU1387301A (en) | 2001-05-14 |
AR026351A1 (es) | 2003-02-05 |
DE50013473D1 (de) | 2006-10-26 |
CN1382122A (zh) | 2002-11-27 |
RU2002113750A (ru) | 2004-01-10 |
CA2389709A1 (en) | 2001-05-10 |
HK1049831A1 (zh) | 2003-05-30 |
ZA200204433B (en) | 2003-09-03 |
US6737436B1 (en) | 2004-05-18 |
EP1230215A1 (de) | 2002-08-14 |
CA2389709C (en) | 2009-02-10 |
AU782477B2 (en) | 2005-08-04 |
ATE339403T1 (de) | 2006-10-15 |
NO20022125L (no) | 2002-05-03 |
BR0015334A (pt) | 2002-07-09 |
EP1230215B1 (de) | 2006-09-13 |
MXPA02004440A (es) | 2004-09-10 |
CZ20021440A3 (cs) | 2002-07-17 |
HUP0203288A2 (hu) | 2003-01-28 |
JP2003513070A (ja) | 2003-04-08 |
KR20020063173A (ko) | 2002-08-01 |
WO2001032618A1 (de) | 2001-05-10 |
NO20022125D0 (no) | 2002-05-03 |
ES2272331T3 (es) | 2007-05-01 |
DE19953025A1 (de) | 2001-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0203288A3 (en) | Pyrrole derivatives as phosphodiesterase vii inhibitors, pharmaceutical compositions containing them and their use | |
HUP0301113A3 (en) | Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors, pharmaceutical compositions containing them and their use | |
HUP0200355A2 (en) | 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use | |
HUP0301722A3 (en) | Pyrimidine derivatives, pharmaceutical compositions containing them and their use | |
HUP0400784A3 (en) | Bicyclic heterocondensated pyrrolcarboxamide derivatives, their use and pharmaceutical compositions containing them | |
HUP0303069A3 (en) | Imidazole derivatives, pharmaceutical compositions containing them and their use | |
HUP0203403A3 (en) | New imidazole derivatives, pharmaceutical compositions containing them and their use | |
HUP0200714A3 (en) | Pharmaceutical compounds, pharmaceutical compositions containing them and their use | |
HUP0302412A3 (en) | Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same | |
HUP0400837A3 (en) | 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them | |
HUP0204474A3 (en) | 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use | |
HUP0203453A3 (en) | Quinazoline derivatives as vegf inhibitors, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0400451A3 (en) | Pyrrole derivatives and pharmaceutical compositions containing them | |
HUP0200804A3 (en) | The use of pharmaceutical compositions containing 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation | |
HUP0200155A3 (en) | Thioamide derivatives, pharmaceutical compositions containing them and their use | |
HUP0300318A3 (en) | Pyrazolobenzodiazepines as cdk2 inhibitors and pharmaceutical compositions containing them and their use | |
HUP0400540A3 (en) | 2-pyrazolin-5-one derivatives, their use and pharmaceutical compositions containing them | |
HUP0105003A2 (en) | 2-oxy-4h-3,1-benzoxazin-4-one derivatives, their use and pharmaceutical compositions containing them | |
HUP0203245A3 (en) | Imidazopyridine derivatives as phosphodiesterase vii inhibitors and pharmaceutical compositions containing them | |
HUP0200996A3 (en) | Amine derivatives, pharmaceutical compositions containing them and their use | |
HUP0203194A3 (en) | Phenylpiperazines, pharmaceutical compositions containing them and their use | |
HUP0400011A3 (en) | Dihydro isoquinoline derivatives as phosphodiesterase inhibitors and pharmaceutical compositions containing them | |
HUP0202075A3 (en) | Substituted 2-dialkylaminoalkylbiphenyl derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0203385A3 (en) | Pyrimidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0300578A3 (en) | Alkylated imidazopyridine derivatives, pharmaceutical compositions containing them and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |